Executive changes at Novartis
Marie-France Tschudin, president, innovative medicines international and chief commercial officer of Novartis (NOVN: VX), has decided to leave the Swiss pharma giant and will step down from the executive committee of Novartis (ECN), effective September 15, after nearly seven years of commercial leadership at Novartis.
As a result, Novartis announced that Dr Patrick Horber, currently senior vice president and president, immunology at AbbVie (NYSE: ABBV) has been appointed as president, international, effective later this year, reporting to chief executive Dr Vas Narasimhan. Dr Horber will become a member of the ECN. Mukul Mehta, chief financial officer, international, will lead the unit ad-interim until Dr. Horber assumes the role.
In his latest role at AbbVie, Dr Horber was responsible for the group’s Immunology Business Unit, leading the global strategy and US execution including global commercial development. Prior to this role he has served in a variety of leadership and general management positions in the US and Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze